Balanced news tone
News Sentiment
JNJ sentiment intelligence
Johnson & Johnson news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-2.3% over one week, +11.7% over four weeks, trend active, and materially above fair value.
Johnson & Johnson (NYSE:JNJ) Rating Increased to Buy at Wall Street Zen
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Johnson & Johnson (NYSE:JNJ) Rating Increased to Buy at Wall Street Zen
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 18 Jul 2026 05:29
- Source
- MarketBeat
Johnson & Johnson (NYSE:JNJ) Shares Up 1.2% - Here's What Happened
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 21:33
- Source
- MarketBeat
Johnson & Johnson (JNJ) Stock Faces Margin Squeeze As Q2 Net Profitability Undercuts Bullish Narrative
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Jul 2026 20:30
- Source
- simplywall.st
Johnson & Johnson $JNJ Shares Acquired by MASTERINVEST Kapitalanlage GmbH
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 09:27
- Source
- MarketBeat
The Real Engine Behind Johnson & Johnson Stock’s Next Climb
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 13:42
- Source
- Trefis
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 18:24
- Source
- MarketBeat
Johnson & Johnson CFO Says Guidance Hike Is Just the Start
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 15 Jul 2026 18:13
- Source
- Barron's
Johnson & Johnson (JNJ) Stock May Be Reasonable After Talc Verdict Ruling
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 14:14
- Source
- Market source
Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 21:50
- Source
- Market source
Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Market source
Why Johnson & Johnson, Altria, Verizon, and Other Safe Dividend Stocks Climbed Today
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 24 Jun 2026 10:44
- Source
- AOL.com
Johnson & Johnson Dividend Stock Analysis: 64 Years of Increases and Current Valuation - News and Statistics
- Tone
- Positive 66/100
- Event
- Capital return
- Published
- 06 Jun 2026 07:00
- Source
- IndexBox
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 25 Mar 2026 07:00
- Source
- Barron's
Johnson & Johnson Remains A Safe Harbor For Investors - Grand Pinnacle Tribune
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Mar 2026 08:00
- Source
- Evrim Ağacı
JNJ stock price today: Why Johnson & Johnson shares dropped despite strong 2026 forecast? Here's what inve
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 21 Jan 2026 08:00
- Source
- The Economic Times
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Nov 2025 08:00
- Source
- CHEManager
Johnson & Johnson Stock To $134?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Oct 2025 07:00
- Source
- Forbes
Johnson & Johnson stock falls after company lays out plan to spin off orthopaedics business
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 14 Oct 2025 07:00
- Source
- The Economic Times
Johnson & Johnson’s Shareholder Supremacy In Healthcare
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Sep 2025 07:00
- Source
- Forbes
Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 13 Jan 2025 08:00
- Source
- Barron's
Johnson & Johnson Foundation funds accelerator to support healthcare innovators in Latin America
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Oct 2024 07:00
- Source
- Johnson & Johnson